The present invention relates to a new compound of formula (I) wherein the variables have the meaning as indicated in the claims; or an enantiomer or salt thereof. The compounds of formula (I) are useful in the control of parasites, in particular endoparasites, in and on vertebrates. ##STR00001##

The present invention relates to a new compound of formula (I) wherein the variables have the meaning as indicated in the claims; or an enantiomer or salt thereof. The compounds of formula (I) are useful in the control of parasites, in particular endoparasites, in and on vertebrates. ##STR00001##

The present disclosure provides carboxamides and sulfonamides having Formula (I): and the pharmacentically acceptable salts and solvates thereof, wherein A, Y, B, X, and Z are defined as set forth in the specification. The present disclosure is also directed to the use of compounds of Formula (I) to treat a disorder responsive to the blockade of SMYD proteins such as SMYD3 or SMYD2. Compounds of the present disclosure are especially useful for treating cancer.

##STR00001##

The present disclosure provides carboxamides and sulfonamides having Formula (I): and the pharmacentically acceptable salts and solvates thereof, wherein A, Y, B, X, and Z are defined as set forth in the specification. The present disclosure is also directed to the use of compounds of Formula (I) to treat a disorder responsive to the blockade of SMYD proteins such as SMYD3 or SMYD2. Compounds of the present disclosure are especially useful for treating cancer.

##STR00001##

A compound represented by Formula (1): ##STR00001##
The compound can be used as insecticides.

A compound represented by Formula (1): ##STR00001##
The compound can be used as insecticides.

The present invention relates to a magnetic particle dispersion, and the magnetic particle dispersion includes a magnetic particle, an isothiazoline compound, and an aqueous medium.

The present invention relates to a magnetic particle dispersion, and the magnetic particle dispersion includes a magnetic particle, an isothiazoline compound, and an aqueous medium.

Described herein are HSD17B13 inhibitors and pharmaceutical compositions comprising said inhibitors. The subject compounds and compositions are useful for the treatment of liver disease, metabolic disease, or cardiovascular disease, such as NAFLD or NASH, or drug induced liver injury (DILI).

The present invention provides a compound having the structure:

##STR00001##

wherein
X.sub.1 is N or CR.sub.5, wherein R.sub.5 is H, OH, halogen or alkyl;
X.sub.2, X.sub.3 and X.sub.4 are each independently NH, N, S, O or CR.sub.6, wherein each R.sub.6 is independently H, OH, halogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, haloalkyl, O(alkyl), S(alkyl), NH.sub.2, NH(alkyl), N(alkyl).sub.2 or CO.sub.2H;
R.sub.1, R.sub.2, R.sub.3 and R.sub.4 are each independently H, F, Cl, Br, I, NO.sub.2, CN, CF.sub.3, CF.sub.2H, OCF.sub.3, -(alkyl), -(haloalkyl), -(alkenyl), -(alkynyl), -(aryl), -(heteroaryl), -(cycloalkyl), -(cycloalkylalkyl), -(heteroalkyl), heterocycle, heterocycloalkyl, -(alkylheteroalkyl), -(alkylaryl), OH, OAc, O-(alkyl), O-(alkenyl), O-(alkynyl), O-(aryl), (heteroaryl), SH, S-(alkyl), S-(alkenyl), S-(alkynyl), S-(aryl), S-(heteroaryl), NH.sub.2, NH-(alkyl), NH-(alkenyl), NH-(alkynyl), NH-(aryl), NH-(heteroaryl), C(O)R.sub.7, S(O)R.sub.7, SO.sub.2R.sub.7, NHSO.sub.2R.sub.7, OC(O)R.sub.7, SC(O)R.sub.7, NHC(O)R.sub.7 or NHC(S)R.sub.7,
wherein R.sub.7 is, H, (alkyl), OH, O(alkyl), NH.sub.2, NH(alkyl) or N(alkyl).sub.2;
B is absent or present, and when present is

##STR00002## wherein R.sub.8 is H, OH, halogen, alkyl, cycloalkyl, cycloalkylalkyl, O-(alkyl), S-(alkyl), NH.sub.2, NH-(alkyl), N(alkyl).sub.2 or CO.sub.2H; and
C is H, substituted or unsubstituted monocycle, bicycle, heteromonocycle, heterobicycle, aryl, heteroaryl, alkyl, cycloalkyl, cycloalkylalkyl, CO.sub.2H, COOR.sub.9, OH, OR.sub.9, NH.sub.2, NHR.sub.9, NR.sub.9R.sub.10, SO.sub.2R.sub.11, CH.sub.2NHR.sub.9, CH.sub.2NR.sub.9R.sub.10 or CH.sub.2COOR.sub.9, wherein R.sub.9 and R.sub.10 are each independently H, alkyl, cycloalkyl, C(O)-alkyl, C(O)-cycloalkyl, C(O)OH, C(O)O-alkyl, C(O)O-cycloalkyl, C(O)NH.sub.2, C(O)NH(alkyl), C(O)NH(cycloalkyl), C(O)N(alkyl).sub.2, CH.sub.2NH(alkyl), CH.sub.2COOH, SO.sub.2CH.sub.3, OH, O(alkyl), NH.sub.2, NH(alkyl) or N(alkyl) wherein R.sub.11 is alkyl, haloalkyl, cycloalkyl, aryl, heteroaryl, NH.sub.2, NH(alkyl), NH(cycloalkyl), NH(heterocycle), NH(aryl), NH(heteroaryl) or NHCOR.sub.12, wherein R.sub.12 is alkyl, haloalkyl, cycloalkyl, heterocycle, aryl or heteroaryl,
or a pharmaceutically acceptable salt thereof.